Is mogamulizumab-induced alopecia areata associated with favorable outcomes in Sézary syndrome?

Amatore, Florent; Dereure, Olivier; Delaporte, Emmanuel; Ram-Wolff, Caroline; Bagot, Martine

Amatore, Florent; Dereure, Olivier; Delaporte, Emmanuel; Ram-Wolff, Caroline; Bagot, Martine.

Afiliação

Amatore F; Department of Dermatology, Aix Marseille University, APHM, North Hospital, Marseille, France.
Dereure O; Department of Dermatology, Montpellier University, Saint-Eloi Hospital, Montpellier, France.
Delaporte E; Department of Dermatology, Aix Marseille University, APHM, North Hospital, Marseille, France.
Ram-Wolff C; Department of Dermatology, Paris University, Saint-Louis Hospital, AP-HP, Paris, France.
Bagot M; Department of Dermatology, Paris University, Saint-Louis Hospital, AP-HP, Paris, France.

Eur J Cancer ; 156 Suppl 1: S50-S51, 2021 Oct.

Article em En | MEDLINE | ID: mdl-34649661

Palavras-chave

Mogamulizumab; alopecia areata; alopecia totalis; immune-related adverse event

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Eur J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google